Re: Sabizabulin - mCRPC- used now for Covid 19.
in response to
by
posted on
Apr 21, 2022 11:57AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
fouremm - "I dread the idea of an IPO because I think the single biggest influence on share price at the time will be millions shares looking to escape current management. "
I agree! Zenith can't handle an IPO without a major success event to drive the price. Otherwise, it will go the other way and financing will be even worse like RVX.